CYTEA|BIO HAS DEVELOPED AND PATENTED A VERSATILE AND MODULAR CELL THERAPY PLATFORM (PIN™ PLATFORM). THE PLATFORM IS UNIQUE IN ITS APPROACH TO UTILIZE UNMODIFIED (THEREFORE POTENT AND SAFE) IMMUNE EFFECTOR CELLS TARGETED TO PATHOLOGICAL CELLS THROUGH RECOGNITION LIGANDS OCCUPYING NATURAL RECEPTORS ON THE THERAPEUTIC CELL SURFACE. THE PIN™ PLATFORM ENABLES VIRTUALLY ANY HUMANIZED MONOCLONAL ANTIBODY TO BE EMPLOYED AS A TARGETING LIGAND AS WELL AS A WIDE RANGE OF FC – BASED CONSTRUCTS.
SIMPLE Fc ENGINEERING ENABLES LIGANDS TO BE FIRMLY BOUND TO THE THERAPEUTIC CELL DURING MANUFACTURE.
THE PIN™ PLATFORM SUPPORTS THERAPEUTIC USES OF BOTH ALLOGENEIC AND AUTOLOGOUS EFFECTOR CELLS WITHOUT ANY MODIFICATIONS. WHEN COMBINED WITH APPROPRIATE SINGLE OR MULTIPLE LIGANDS, AN ALMOST UNLIMITED NUMBER OF DRUG SUBSTANCES ARE POSSIBLE, PROVIDING SENSING, TARGETING ACTIVATION AND POTENT THERAPEUTIC EFFECT WITH LOW DEVELOPMENT RISK AND POSITIVE ECONOMICS.
80, AVENUE AUGUSTIN FLICHE,
34295 MONTPELLIER CEDEX 5,
FRANCE
AVENUE DES PLANCHES 20C,
1820 MONTREUX, SWITZERLAND
CYTEA|BIO IS A PIPELINE COMPANY OF MEDXCELL
VISIT MEDXCELL’S WEBSITE FOR MORE INFORMATION© CYTEA|BIO / ALL RIGHTS RESERVED / DATA POLICY